Analyst Ratings For Blueprint Medicines Corp (NASDAQ:BPMC)
Today, Wedbush reiterated its Outperform rating on Blueprint Medicines Corp (NASDAQ:BPMC) with a price target of $101.00.
There are 9 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Blueprint Medicines Corp (NASDAQ:BPMC) is Buy with a consensus target price of $93.75 per share, a potential 38.03% upside.
Some recent analyst ratings include
- 10/22/2018-Blueprint Medicines Corp (NASDAQ:BPMC) had its Outperform rating reiterated by Wedbush with a $101.00 price target
- 10/7/2018-Blueprint Medicines Corp (NASDAQ:BPMC) had its Buy rating reiterated by Cowen
- 9/25/2018-Blueprint Medicines Corp (NASDAQ:BPMC) has coverage initiated with a Outperform ➝ Outperform rating and $105.00 price target
- 9/18/2018-Blueprint Medicines Corp (NASDAQ:BPMC) has coverage initiated with a Buy rating and $102.00 price target
- On 9/17/2018 Marion Dorsch, Insider, sold 2,300 with an average share price of $70.47 per share and the total transaction amounting to $162,081.00.
- On 8/6/2018 Jeffrey W Albers, CEO, sold 20,000 with an average share price of $70.59 per share and the total transaction amounting to $1,411,800.00.
- On 5/7/2018 Jeffrey W Albers, CEO, sold 20,000 with an average share price of $78.90 per share and the total transaction amounting to $1,578,000.00.
- On 3/19/2018 George Demetri, Director, sold 5,492 with an average share price of $100.09 per share and the total transaction amounting to $549,694.28.
- On 3/15/2018 Marion Dorsch, Insider, sold 2,300 with an average share price of $100.07 per share and the total transaction amounting to $230,161.00.
- On 3/2/2018 Jeffrey W Albers, CEO, sold 20,000 with an average share price of $92.57 per share and the total transaction amounting to $1,851,400.00.
- On 2/28/2018 Nicholas Lydon, Director, sold 25,000 with an average share price of $87.89 per share and the total transaction amounting to $2,197,250.00.
About Blueprint Medicines Corp (NASDAQ:BPMC)
Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V mutations, that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors and systemic mastocytosis; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma. It is also developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or translocations; and RET resistant mutants that would arise from treatment with first generation therapies. In addition, the company is developing BLU-782, a discovery program targeting the kinase ALK2 for the treatment of fibrodysplasia ossificans progressiva, a rare genetic disease caused by mutations in the ALK2 gene, ACVR1. The company has an agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to discover, develop, and commercialize small molecule therapeutics targeting kinases. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.
Recent Trading Activity for Blueprint Medicines Corp (NASDAQ:BPMC)
Shares of Blueprint Medicines Corp closed the previous trading session at 67,92 −1,77 2,54 % with 67.52 shares trading hands.
